マーケットレポート詳細

マイクロバイオーム治療：世界市場2027年予測

Microbiome Therapeutics: Global Markets

出版元：BCC Research 　 出版元について
発行年：2023年1月
定価 Single User License(1名様ライセンス)US$5,500 (米国ドル) /2 to 5 Users License(5名様)$6,600 /Site License $7,920 / Enterprise License $9,504
ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
ご請求は円換算（お見積り日TTSレート）となります。
納品形態：PDF by Email
当調査レポートは英文175ページになります。
商品コード：BCC445

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。

【レポート紹介】

マイクロバイオーム治療の世界市場規模2021年で1億4170万ドル、2026年に13億ドル、市場の平均年成長率は56.4%になると推測されます。
当レポートでは、市場概要、市場ダイナミクス、各種セグメント別市場分析(治療タイプ別、用途別、国地域別)、特許分析、競合状況、主要企業プロフィールなどを盛り込み、概略以下の構成でお届けいたします。

【レポート構成概要】

◆イントロダクション

・調査目的
・調査対象
・調査手法

◆サマリーと調査ハイライト

◆市場/技術背景

・ベネフィット
・ヒトマイクロバイオーム
・マイクロバイオーム治療

◆治療タイプ別市場

・加法療法(Additive Therapeutics)
・調整療法(Modulatory Therapeutics)
・減法療法(Subtractive Therapeutics)
※市場予測データ-2027掲載

◆疾患タイプ別市場

・感染症
・消化器系疾患
・代謝疾患
・がん
・腸脳相関疾患
・その他疾患
※市場予測データ-2027掲載
※疾患タイプ別に地域別の細分化データ掲載

◆業界構造

・マイクロバイオーム治療薬への投資
・提携、協力
・ライセンシングおよび製造契約
・M&A
・主要企業
・業界リーダーによる洞察

◆特許分析

・年別

・タイプ別
・疾患タイプ別
・企業別
・国別
・譲受人別

◆臨床治験

・疾患カテゴリー別
・治療タイプ別
・企業別

◆市場機会分析

・SWOT分析

◆マイクロバイオーム治療の主要企業プロフィール

4D PHARMA
AO BIOME LLC
ASSEMBLY BIOSCIENCES INC.
ARMATA PHARMACEUTICALS
AZITRA INC.
BIOMICA
BIOMX
CHAIN BIOTECHNOLOGY LTD.
ELIGO BIOSCIENCE SAS
ENTEROME SA
EVELO BIOSCIENCES
FINCH THERAPEUTICS GROUP INC.
INTRALYTIX INC.
MAAT PHARMA
OSEL INC.
PYLUM BIOSCIENCES INC.
QUORUM INNOVATIONS LLC
REBIOTIX INC. (A FERRING COMPANY)
SECOND GENOME
SENDA BIOSCIENCES INC.
SERES THERAPEUTICS INC.
SFA THERAPEUTICS INC.
SYNLOGIC
THERIVA BIOLOGICS INC.
VEDANTA BIOSCIENCES INC.
YSOPIA BIOSCIENCE INC.
（全175頁）


【レポート詳細目次、データ項目一覧は当ページ下を参照ください】

Table of Contents (英文詳細目次）

Chapter 1 Introduction

1.1 Study Goals and Objectives
1.2 Reasons for Doing This Study
1.3 What's New in This Report?
1.4 Scope of Report
1.5 Information Sources
1.6 Methodology
1.7 Geographic Breakdown
1.8 Analyst's Credentials
1.9 BCC Custom Research
1.10 Related BCC Research Reports

Chapter 2 Summary and Highlights

2.1 Key Highlights

Chapter 3 Market and Technology Background

3.1 Benefits
3.2 The Human Microbiome

  • 3.2.1 Different Microbiomes in Humans
  • 3.2.2 Microbiome, Human Health and Disease
  • 3.2.3 Technologies Aiding Microbiome Research
  • 3.2.4 Microbiome Research Projects

3.3 Microbiome Therapeutics

  • 3.3.1 Strategies for the Development of Microbiome Therapeutics
  • 3.3.2 Microbiome Therapeutics Disease Areas
  • 3.3.3 Regulatory Landscape for Microbiome Therapeutics

Chapter 4 Market Breakdown by Type of Therapeutic

4.1 Introduction
4.2 Market Overview

  • 4.2.1 Market Revenue
  • 4.2.2 Market Shares

4.3 Additive Microbiome Therapeutics

  • 4.3.1 Fecal Microbiota Transplants (FMTs)
  • 4.3.2 Live Biotherapeutic Products (LBPs)
  • 4.3.3 Market Overview
  • 4.3.4 Market Revenue
  • 4.3.5 Market Shares

4.4 Modulatory Microbiome Therapeutics

  • 4.4.1 Mechanism of Action
  • 4.4.2 Current Status
  • 4.4.3 Market Overview
  • 4.4.4 Market Revenue
  • 4.4.5 Market Shares

4.5 Subtractive Microbiome Therapeutics

  • 4.5.1 Mechanism of Action
  • 4.5.2 Current Status
  • 4.5.3 Market Overview
  • 4.5.4 Market Revenue
  • 4.5.5 Market Shares

Chapter 5 Market Breakdown by Application

5.1 Introduction

  • 5.1.1 Market Revenue
  • 5.1.2 Market Shares

5.2 Infections

  • 5.2.1 Clostridium Difficile Infection (CDI)
  • 5.2.2 Urinary Tract Infection (UTI)
  • 5.2.3 COVID-19
  • 5.2.4 Market Overview
  • 5.2.5 Market Revenue

5.3 Gastrointestinal (GIT) Diseases

  • 5.3.1 Market Overview
  • 5.3.2 Market Revenue

5.4 Metabolic Diseases

  • 5.4.1 Market Overview
  • 5.4.2 Market Revenue

5.5 Cancer

  • 5.5.1 Market Overview
  • 5.5.2 Market Revenue

5.6 Gut-Brain Axis Diseases

  • 5.6.1 Market Overview
  • 5.6.2 Market Revenue

5.7 Other Diseases

  • 5.7.1 Market Overview
  • 5.7.2 Market Revenue

5.8 Regional Markets Globally

  • 5.8.1 Market Shares

Chapter 6 Industry Structure

6.1 Investment in Microbiome Therapeutics

  • 6.1.1 Public Funding Initiatives
  • 6.1.2 Private Funding Initiatives

6.2 Collaborations and Partnerships
6.3 Licensing and Manufacturing Agreements
6.4 Mergers and Acquisitions
6.5 Leading Market Players in the Market for Microbiome Therapeutics

  • 6.5.1 Leading Market Players in Market for Additive Microbiome Therapeutics
  • 6.5.2 Leading Market Players in the Market for Modulatory Microbiome Therapeutics
  • 6.5.3 Leading Market Players in the Market for Subtractive Microbiome Therapeutics

6.6 BCC Research Select Insights from Industry Leaders

Chapter 7 Patent Analysis

7.1 Patent Analysis

  • 7.1.1 Patents by Year
  • 7.1.2 Patents by Type
  • 7.1.3 Patents by Type of Disease
  • 7.1.4 Patents by Company
  • 7.1.5 Patents by Country
  • 7.1.6 Patents by Assignee

Chapter 8 Clinical Trials

8.1 Clinical Trials by Disease Category

  • 8.1.1 Distribution Shares of Clinical Trials

8.2 Clinical Trials by Type of Therapeutic

  • 8.2.1 Distribution Shares of Clinical Trials by Type of Therapeutic

8.3 Clinical Trials by Company

  • 8.3.1 Distribution Shares of Clinical Trials by Company
  • 8.3.2 Microbiome Therapeutics in Discovery and Preclinical Development
  • 8.3.3 Microbiome Therapeutics in Phase 3 Clinical Trials

Chapter 9 Analysis of Market Opportunities

9.1 SWOT Analysis

  • 9.1.1 Strengths of Market for Microbiome Therapeutics
  • 9.1.2 Challenges in the Market for Microbiome Therapeutics
  • 9.1.3 Opportunities in the Market for Microbiome Therapeutics
  • 9.1.4 Threats to the Market for Microbiome Therapeutics

Chapter 10 Company Profiles

4D PHARMA
AO BIOME LLC
ASSEMBLY BIOSCIENCES INC.
ARMATA PHARMACEUTICALS
AZITRA INC.
BIOMICA
BIOMX
CHAIN BIOTECHNOLOGY LTD.
ELIGO BIOSCIENCE SAS
ENTEROME SA
EVELO BIOSCIENCES
FINCH THERAPEUTICS GROUP INC.
INTRALYTIX INC.
MAAT PHARMA
OSEL INC.
PYLUM BIOSCIENCES INC.
QUORUM INNOVATIONS LLC
REBIOTIX INC. (A FERRING COMPANY)
SECOND GENOME
SENDA BIOSCIENCES INC.
SERES THERAPEUTICS INC.
SFA THERAPEUTICS INC.
SYNLOGIC
THERIVA BIOLOGICS INC.
VEDANTA BIOSCIENCES INC.
YSOPIA BIOSCIENCE INC.
Chapter 11 Appendix: Acronyms

List of Tables

Summary Table : Global Market for Microbiome Therapeutics, by Type of Disease, Through 2027
Table 1 : Technology for Microbiome Research
Table 2 : Dysbiosis in Microbiome
Table 3 : Leading Pharmaceutical/Microbiome Therapeutics Partnerships
Table 4 : Global Market for Microbiome Therapeutics, by Type, Through 2027
Table 5 : Global Market Shares of Microbiome Therapeutics, by Type, 2027
Table 6 : LBPs in Microbiome Therapeutics
Table 7 : Global Market for Additive Microbiome Therapeutics, by Type, Through 2027
Table 8 : Global Market Shares of Additive Microbiome Therapeutics, by Type, 2027
Table 9 : Modulatory Microbiome Therapeutics
Table 10 : Global Market for Modulatory Microbiome Therapeutics, by Type, Through 2027
Table 11 : Global Market Shares of Modulatory Microbiome Therapeutics, by Type, 2027
Table 12 : Global Market for Subtractive Microbiome Therapeutics, by Type, Through 2027
Table 13 : Global Market Shares of Subtractive Microbiome Therapeutics, by Type, 2027
Table 14 : R&D Expenditures in Microbiome Therapeutics, by Company, 2017-2019
Table 15 : Global Market for Microbiome Therapeutics, by Type of Disease, Through 2027
Table 16 : Global Market Shares of Microbiome Therapeutics, by Type of Disease, 2027
Table 17 : Microbiome Therapeutics for Infections
Table 18 : Global Market for Microbiome Therapeutics for Infections, by Region, Through 2027
Table 19 : Microbiome Therapeutics for GIT Diseases
Table 20 : Global Market for Microbiome Therapeutics for GIT Diseases, by Region, Through 2027
Table 21 : Microbiome Therapeutics for Metabolic Diseases
Table 22 : Global Market for Microbiome Therapeutics for Metabolic Diseases, by Region, Through 2027
Table 23 : Microbiome Therapeutics for Cancer
Table 24 : Global Market for Microbiome Therapeutics for Cancer, by Region, Through 2027
Table 25 : Microbiome Therapeutics for Gut-Brain Axis Diseases
Table 26 : Global Market for Microbiome Therapeutics for Gut-Brain Axis Diseases, by Region, Through 2027
Table 27 : Microbiome Therapeutics for Other Diseases
Table 28 : Global Market for Microbiome Therapeutics for Other Diseases, by Region, Through 2027
Table 29 : Global Market for Microbiome Therapeutics, by Region, Through 2027
Table 30 : Global Market Shares of Microbiome Therapeutics, by Region, 2027
Table 31 : Historical Funding Activity, Microbiome Therapeutics, 2015 and 2016
Table 32 : Public Funding, Microbiome Therapeutics, 2018-2022
Table 33 : Venture Funding, Microbiome Therapeutics, 2017-Aug. 2020
Table 34 : Collaborations and Partnerships in the Market for Microbiome Therapeutics, 2017-2022
Table 35 : Licensing and Manufacturing Agreements in the Market for Microbiome Therapeutics, 2017-Aug. 2020
Table 36 : Leading Developers of Additive Microbiome Therapeutics, 2022
Table 37 : Leading Developers of Modulatory Microbiome Therapeutics, 2022
Table 38 : Leading Developers of Subtractive Microbiome Therapeutics, 2022
Table 39 : Patents Issued on Microbiome Therapeutics, by Year, 2017–2022
Table 40 : Patents Issued on Microbiome Therapeutics, by Type, 2017–2022
Table 41 : Patents Issued on Microbiome Therapeutics, by Type of Disease, 2017–2022
Table 42 : Patents Issued on Microbiome Therapeutics, by Company, 2017–2022
Table 43 : Patents Issued on Microbiome Therapeutics, by Country, 2017–2022
Table 44 : Patents Issued on Microbiome Therapeutics, by Assignee, 2017–Aug. 2020
Table 45 : Distribution of Clinical Trials on Microbiome Therapeutics, by Type of Disease, 2022
Table 46 : Distribution Shares of Clinical Trials on Microbiome Therapeutics, by Type of Disease, 2022
Table 47 : Distribution Shares of Clinical Trials on Microbiome Therapeutics, by Type of Therapeutic
Table 48 : Distribution Shares of Clinical Trials on Microbiome Therapeutics, by Type of Therapeutic
Table 49 : Distribution Shares of Clinical Trials on Microbiome Therapeutics, by Company
Table 50 : Distribution Shares of Clinical Trials on Microbiome Therapeutics for the Top 10 Companies
Table 51 : Microbiome Therapeutics, Discovery and Preclinical Development
Table 52 : Microbiome Therapeutics in Phase 3 Clinical Trials
Table 53 : 4D Pharma: Pipeline
Table 54 : AO Biome: Pipeline
Table 55 : Assembly Biosciences: Pipeline
Table 56 : Armata Pharmaceuticals: Pipeline
Table 57 : Azitra: Pipeline
Table 58 : Biomica: Pipeline
Table 59 : BiomX: Pipeline
Table 60 : Enterome: Pipeline
Table 61 : Evelo Biosciences: Pipeline
Table 62 : Finch Therapeutics: Pipeline
Table 63 : Intralytix: Pipeline
Table 64 : MaaT Pharma: Pipeline
Table 65 : Osel: Pipeline
Table 66 : Quorum Innovations: Pipeline
Table 67 : Rebiotix: Pipeline
Table 68 : Second Genome: Pipeline
Table 69 : Seres Therapeutics: Pipeline
Table 70 : SFA Therapeutics: Pipeline
Table 71 : Synlogic: Pipeline
Table 72 : Theriva Biologics: Pipeline
Table 73 : Vedanta Biosciences: Pipeline
Table 74 : Ysopia Bioscience: Pipeline
Table 75 : Acronyms Used in This Report

List of Figures

Summary Figure : Global Market for Microbiome Therapeutics, by Type of Disease, 2021-2027
Figure 1 : Differences between the Human Genome and the Microbiome
Figure 2 : Bacterial Distribution, by Body Site
Figure 3 : Essential Functions, Human Microbiome
Figure 4 : Dysbiosis and Human Health
Figure 5 : Summary of NIH Funding for Microbiome Research, 2012-2016
Figure 6 : Global Market for Microbiome Therapeutics, by Type, 2021-2027
Figure 7 : Global Market Shares of Microbiome Therapeutics, by Type, 2027
Figure 8 : Global Market for Additive Microbiome Therapeutics, by Type, 2021-2027
Figure 9 : Global Market Shares of Additive Microbiome Therapeutics, by Type, 2027
Figure 10 : Global Market for Modulatory Microbiome Therapeutics, by Type, 2021-2027
Figure 11 : Global Market Shares of Modulatory Microbiome Therapeutics, by Type, 2027
Figure 12 : Global Market for Subtractive Microbiome Therapeutics, by Type, 2021-2027
Figure 13 : Global Market Shares of Subtractive Microbiome Therapeutics, by Type, 2027
Figure 14 : Global Market for Microbiome Therapeutics, by Type of Disease, 2021-2027
Figure 15 : Global Market Shares of Microbiome Therapeutics, by Type of Disease, 2027
Figure 16 : Global Market for Microbiome Therapeutics for Infections, by Region, 2021-2027
Figure 17 : Global Market for Microbiome Therapeutics for GIT Diseases, by Region, 2021-2027
Figure 18 : Global Market for Microbiome Therapeutics for Metabolic Diseases, by Region, 2021-2027
Figure 19 : Global Market for Microbiome Therapeutics for Cancer, by Region, 2021-2027
Figure 20 : Global Market for Microbiome Therapeutics for Gut-Brain Axis Diseases, by Region, 2021-2027
Figure 21 : Global Market for Microbiome Therapeutics for Other Diseases, by Region, 2021-2027
Figure 22 : Global Market for Microbiome Therapeutics, by Region, 2021-2027
Figure 23 : Global Market Shares of Microbiome Therapeutics, by Region, 2027
Figure 24 : Patents Issued on Microbiome Therapeutics, by Year, 2017-2022
Figure 25 : Patents Issued on Microbiome Therapeutics, by Type, 2017-2022
Figure 26 : Patents Issued on Microbiome Therapeutics, by Type of Disease, 2017–2022
Figure 27 : Patents Issued on Microbiome Therapeutics, by Company, 2017-2022
Figure 28 : Patents Issued on Microbiome Therapeutics, by Country, 2017–2022
Figure 29 : Patents Issued on Microbiome Therapeutics, by Assignee, 2017–Aug. 2020
Figure 30 : Distribution Shares of Clinical Trials on Microbiome Therapeutics, by Type of Disease, 2022
Figure 31 : Distribution Shares of Clinical Trials on Microbiome Therapeutics by Type of Therapeutic
Figure 32 : Distribution Shares of Clinical Trials on Microbiome Therapeutics for the Top 10 Companies
Figure 33 : SWOT Analysis of the Market for Microbiome Therapeutics


△ 一番上に戻る